Related Experiment Video
Updated: May 22, 2026
12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
Cinnamon in glycaemic control: Systematic review and meta analysis
Rajadurai Akilen1, Amalia Tsiami, Devasenan Devendra
1Faculty of Health and Human Science, University of West London, Paragon House, Boston Manor Road, Brentford TE8 9GA, UK. raj.akilen@uwl.ac.uk
Clinical Nutrition (Edinburgh, Scotland)
|May 15, 2012
Summary
Cinnamon supplementation may improve blood sugar control in individuals with type 2 diabetes. This review found cinnamon significantly reduced HbA1c and fasting plasma glucose (FPG) levels.
Area of Science:
- Endocrinology
- Metabolic Disorders
- Nutritional Science
Background:
- Cinnamon exhibits bioactive properties, potentially mimicking insulin's action by enhancing glucose uptake in adipose and skeletal tissues.
- Type 2 Diabetes Mellitus (T2DM) is a metabolic disorder characterized by impaired glucose regulation.
Purpose of the Study:
- To systematically review and meta-analyze the effects of cinnamon on glycemic control in patients diagnosed with Type 2 Diabetes Mellitus.
Main Methods:
- A comprehensive literature search was performed up to August 2011, utilizing MeSH and Medline terms for cinnamon and diabetes mellitus.
- Six randomized controlled trials (RCTs) involving 435 patients met the inclusion criteria, with follow-up periods ranging from 40 days to 4 months and daily doses of 1-6g.
Main Results:
- Meta-analysis revealed a statistically significant reduction in mean Hemoglobin A1c (HbA1c) by 0.09% (95% CI: 0.04-0.14).
- A significant decrease in mean fasting plasma glucose (FPG) was observed, measuring 0.84 mmol/l (95% CI: 0.66-1.02).
Conclusions:
- Cinnamon consumption demonstrates a positive impact on glycemic control, specifically on HbA1c and FPG levels.
- Short-term use (<4 months) of cinnamon appears promising for managing glycemic control in T2DM patients.
Related Concept Videos
01:15Diabetes: Management and Pharmacotherapy
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
01:06Oral Hypoglycemic Agents: Glinides
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Acarbose and miglitol are typically...
01:22Diabetes Mellitus: Type 2 and Gestational
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
01:26Hypoglycemia
Hypoglycemia is a blood glucose level below 70 mg/dL. It commonly occurs in individuals using insulin or insulin-secreting drugs, but may also arise in non-diabetic conditions. People with type 1 diabetes are at the highest risk because they depend on exogenous insulin. People with type 2 diabetes are also at risk, especially when treated with insulin or medications such as sulfonylureas, which increase insulin release regardless of blood glucose levels. It develops when insulin levels exceed...